BioNote Altman Z-Score
The Altman Z-Score of BioNote (377740.KS) as of Oct 9, 2026 is 8.64. In the previous year, Altman Z-Score was 6.59 — a change of 31.19% (higher).
Get this data via API
Financial Data API
Altman Z-Score
8.64
YoY
31.19%
Last updated:
Altman Z-Score of BioNote is 2025 8.64 . Altman Z-Score of BioNote was 2024 6.59 . It decreases by 31.19% higher compared to the previous year.
The BioNote Altman Z-Score history
3 Years
10 Years
25 Years
Max
Altman Z-Score
Date
Altman Z-Score
Jan 1, 2019
17.26 KRW
Jan 1, 2020
5.90 KRW
Jan 1, 2021
4.10 KRW
Jan 1, 2022
4.08 KRW
Jan 1, 2023
10.20 KRW
Jan 1, 2024
6.59 KRW
Jan 1, 2025
8.64 KRW
| YEAR | Altman Z-Score | YoY |
|---|---|---|
| 8.64 | +31.19% | |
| 6.59 | -35.40% | |
| 10.20 | +149.94% | |
| 4.08 | -0.57% | |
| 4.10 | -30.48% | |
| 5.90 | -65.79% | |
| 17.26 | — |
Access this data via the Eulerpool API
BioNote Stock analysis
What does BioNote do? BioNote is one of the most popular companies on Eulerpool.
Frequently Asked Questions about BioNote stock
Altman Z-Score of BioNote is 8.64 in 2025.
On Eulerpool you can find the complete historical development of Altman Z-Score BioNote since 2006 – with annual values, charts, and detailed analysis.
The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.
Access this data via the Eulerpool API
Quality — BioNote
All Key Metrics — BioNote
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth